Grant of Options and PDMR dealing

Feedback

10/07/2025 07:00

RNS Number : 4480Q

Feedback PLC

10 July 2025

 

 

Feedback plc

 

Grant of Options and PDMR dealing

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces that it has granted a total of 254,117 options to subscribe for new ordinary shares of 1 penny each in the Company ("Ordinary Shares") under the Company's EMI Share Option Scheme (the "Options") to a person discharging managerial responsibilities (PDMR) and other employees, as detailed below.

 

The Options are being issued to appropriately incentivise and retain talent, as well as to ensure their interests are aligned with that of the Company and its Shareholders. The Options are exercisable at a price of 20 pence per share, reflecting the price at which the Company last completed an equity fundraise in November 2024 and representing a premium of 37.9 per cent to the closing share price on the last trading day before this announcement.

 

219,073 Options are being granted to a PDMR as set out below. The Options will vest in four equal tranches as follows:

 

·      25% vest in three equal sub-tranches annually (8.33% on each of the first, second and third anniversary of grant of 10 July 2025)

·      25% vest on reported revenue of £8m

·      25% vest on reported revenue of £12m; and

·      25% vest on reported revenue of £20m

 

"Reported Revenue" is either:

·      a year's revenue reported in the full year audited financial statements; or

·      12 months' revenue being H2 of the last full year audited financial statements plus H1 of the last published interim financial statements.

 

Options being granted to the PDMR which are subject to the vesting conditions above:

 

Number of Options granted
Total options held (including existing options)
Mark Fletcher, Director of External Affairs*
219,073
219,073

 

* Employed by Feedback Medical Limited, a 100% subsidiary of Feedback plc

 

In addition, 35,044 Options were awarded to four employees on 10 July 2025 with the same exercise price and vesting conditions as the PDMR as set out above.

 

The Options are exercisable for a period of 5 years from the vesting date.

 

The Options represent in aggregate 0.6% of the Company's existing issued share capital.

 

Following the grant of the Options and taking into account existing options, the Company has a total of 4,042,913 options to subscribe for ordinary shares in the Company in issue, representing 9.2% of the Company's issued share capital at the date of this announcement.

 

The FCA notifications, made in accordance with the requirements of the EU Market Abuse Regulation, are appended below.

 

Further information on Feedback and its products can be found on the Company's website: https://feedbackmedical.com

 

-Ends-

  

 

 

Enquiries:

 

Feedback plc
Tom Oakley, CEO
Anesh Patel, CFO
+44 (0) 20 3997 7634
IR@fbk.com
Panmure Liberum Limited (NOMAD and Broker)
Emma Earl/Mark Rogers (Corporate Finance)
Rupert Dearden (Corporate Broking)
+44 (0)20 7886 2500
Walbrook PR Ltd;
Tel: 020 7933 8780 orfeedbackplc@walbrookpr.com
Nick Rome/Joe Walker
07748 325 236 or 07407 020 470

 

 

About Feedback plc

 

Feedback plc liberates the data and knowledge from multiple healthcare IT systems and delivers better workflow to enable clinicians to communicate, collaborate and provide the best healthcare for their patients. We connect care settings with diagnostic and other relevant data to drive better, faster, safer decision that improve outcomes for patients.

 

By linking different clinical systems together into a seamless view of the patient, we can streamline patient pathways and deliver a digital health and diagnostics record across multiple care providers.

 

Bleepa® is our communication and collaboration platform that displays clinical results at a certified and regulated quality, which enables multi-disciplinary team working and diagnostic-enhanced advice and guidance. CareLocker® is our patient-facing platform that gives patients access and control over their diagnostic and other clinical data.

 

The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

 

https://fbk.com

 

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities under UK MAR

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mark Fletcher
2
Reason for the notification
a)
Position/status
PDMR -Director of External Affairs of Feedback Medical Limited
b)
Initial notification /Amendment
Initial
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Feedback plc
b)
LEI
213800UGOF2GT2U2RV90
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 1 penny each
GB00BJN59X09
b)
Nature of the transaction
Grant of options to subscribe for Ordinary Shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
Nil
219,073
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
10 July 2025
f)
Place of the transaction
Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHKKLFBEDLZBBL